Pancragen

Overview

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia’s St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

Mechanism of action

Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

Key research findings

• Corrects impaired glucose tolerance
• Normalizes insulin levels
• Normalizes C-peptide levels
• Improves endocrine pancreatic function
• Supports pancreatic cell differentiation
• Regulates melatonin expression
• Reduces metabolic syndrome incidence
• Upregulates key pancreatic transcription factors

Research applications

Metabolic Support

• Impaired Glucose Tolerance — Corrects age-related glucose tolerance disturbances in primate studies.
• Metabolic Syndrome — Reduces incidence and magnitude of metabolic syndrome.
• Blood Sugar Regulation — Helps control blood sugar through pancreatic function support.

Pancreatic Health

• Pancreatic Cell Differentiation — Impacts differentiation of pancreatic cells during aging.
• Endocrine Function — Improves endocrine function of the pancreas.
• Age-Related Pancreatic Decline — Addresses age-related imbalance of pancreatic function.

Anti-Aging

• Gene Expression Regulation — Directly interacts with DNA to regulate pancreatic gene expression.